#15 Pfizer — Strategic Initiative & Reskilling | Global Intelligence Report 2024-2026

Revenue

$58B

Seagen Acquisition

$43B

ADC Pipeline

20+ assets

Workforce Reduction

10%

Key Strategic Initiative — Review 1: Restructuring Profile

Post-COVID Portfolio Restructuring & Oncology Pivot

Portfolio Restructuring / R&D Reinvention Stage: Implementation

Pfizer used its $70B Paxlovid/vaccine windfall to acquire Seagen ($43B) and reshape its R&D portfolio toward oncology. Simultaneously restructured commercial operations reducing workforce by 10%. The Seagen acquisition added 4 approved ADC (antibody-drug conjugate) cancer drugs and 20+ pipeline assets, requiring complete reskilling of R&D, medical affairs, and commercial teams.

: SKILL GAPS + WORKFORCE -->

Review 2: Reskilling Imperatives — Skill Gap Analysis

Scientific + Commercial

Oncology R&D methodologies

92%

AI-assisted drug design

88%

ADC (antibody-drug conjugate) therapeutics

85%

Clinical data science

83%

Portfolio strategy & prioritization

80%

Regulatory oncology submissions

86%

Affected Workforce Segments

Research scientistsClinical trial managersCommercial teamsMedical affairsRegulatory affairs

Learning Infrastructure Required

Pfizer Learning Hub (digital platform)
Seagen integration learning centers
Partnership with FDA for oncology regulatory training

FULL WIDTH -->

Recommended Learning & Reskilling Modalities

1Pfizer Learning Hub oncology tracks
2Seagen integration training
3AI drug discovery certification
4ADC therapeutic masterclasses